EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions

Simona Rizea-Savu, Simona Nicoleta Duna, Adrian Ghita, Adriana Iordachescu, Ioana Garlea, Marinela Chirila

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1471 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Simona Rizea-Savu und 5 weiteren Autor:innen. Beteiligte Einrichtung: 3S-Pharmacological Consultation & Research GmbH, Harpstedt, Germany. Hauptthemen laut MEDLINE: Drugs, Generic, Platelet Aggregation Inhibitors, Ticagrelor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ticagrelor is a key antiplatelet agent used to prevent thrombotic events in patients with acute coronary syndrome. This open‐label, 2‐period, crossover Phase I study assessed the pharmacokinetics and bioequivalence of a generic ticagrelor 90‐mg formulation compared to the innovator product under fasting conditions. Twenty‐eight healthy White adults participated in the study. Each participant received a single dose of either the test or reference formulation, followed by a 7‐day washout period before switching to the alternate formulation. Plasma concentrations of ticagrelor were measured using a validated high‐performance liquid chromatography‐tandem mass spectrometry method. Statistical analysis of primary pharmacokinetic parameters, including maximum concentration and area under the plasma concentration‐time curve from time 0 to the last quantifiable concentration, showed bioequivalence with test/reference ratios of 110.9% and 107.1%, respectively, and 90% confidence intervals within the 80%‐125% regulatory range. Treatment‐emergent adverse events, such as headache, dysphagia, and dizziness, were moderate and transient and resolved promptly, with no significant difference in incidence between the formulations. These results confirm that the generic ticagrelor formulation is bioequivalent to the innovator product, supporting its use as an interchangeable option in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericPlatelet Aggregation InhibitorsTicagrelorAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveChromatography, High Pressure LiquidCross-Over StudiesFastingHealthy VolunteersTandem Mass SpectrometryTherapeutic EquivalencyWhite People

Stichwörter der Autor:innen

HPLC–tandem mass spectrometrybioavailabilitybioequivalencepharmacokineticsticagrelor

Substanzen

Drugs, GenericPlatelet Aggregation InhibitorsTicagrelor

Autor:innen und Institutionen

  • 3S-Pharmacological Consultation & Research GmbH, Harpstedt, Germany.
  • Titu Maiorescu University, Bucharest, Romania.
  • 3S-Pharmacological Consultation & Res. SRL, Bucharest, Romania.
  • Pharma Serv International SRL, Bucharest, Romania.
  • Medochemie Ltd, Cyprus.

Zitieren

APA

Rizea-Savu, S., Duna, S. N., Ghita, A., Iordachescu, A., Garlea, I., & Chirila, M. (2025). Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1471

Vancouver

Rizea-Savu S, Duna SN, Ghita A, Iordachescu A, Garlea I, Chirila M. Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1471

BibTeX
@article{RizeaSavu2025,
  author = {Rizea-Savu, Simona and Duna, Simona Nicoleta and Ghita, Adrian and Iordachescu, Adriana and Garlea, Ioana and Chirila, Marinela},
  title = {Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1471}
}
Kostenlos starten →